ABSTRACT
INTRODUCTION
Although curative therapies exist for organ-confined or locally advanced prostate cancer, treatment options are limited for metastatic castrate-resistant prostate cancer (CRPC). Progression to CRPC is defined by resistance to androgen deprivation therapy, which typically occurs less than three years after initiation of androgen deprivation therapy (1) (2) (3) . The transition from androgen-dependent prostate cancer to CRPC is not fully understood. Androgen receptor (AR) signaling is known to be maintained despite low levels of circulatory androgens (1) , which has been attributed to numerous mechanisms, including: 1) AR gene amplification (4); 2) AR ligand-binding domain mutations conferring ligand promiscuity (5, 6); 3) intracrine androgen biosynthesis within prostate cancer cells from adrenal steroids and cholesterol (7, 8) ; 4) ligand-independent, non-canonical AR transactivation by kinase signaling pathways (9, 10); 5) upregulation of constitutively active, AR splice variants which do not require ligand to support prostate cancer growth (11, 12) .
Most therapeutic strategies for prostate cancer are directed at the AR signaling axis, with established antiandrogens such as Flutamide and Bicalutamide being joined by recently U.S. Food and Drug Administration-approved agents such as the androgen biosynthesis inhibitor abiraterone acetate (Zytiga®) (13, 14) and the second-generation antiandrogen MDV3100 (Enzalutamide, Xtandi®) (14) . The first-generation antiandrogens function by competitive inhibition of androgen binding to AR (15, 16) and by altering coactivator and corepressor recruitment to induce formation of a transcriptionally inactive AR complex (16) . The second-generation antiandrogen MDV3100 induces a distinct conformational change in AR which impairs AR nuclear localization and DNA binding (17) .
Signal transducer and activator of transcription 5a/b (Stat5a/b) provides a non-AR therapeutic target protein in prostate cancer (18) (19) (20) (21) (22) (23) (24) (25) (26) . Transcription factor Stat5a/b is composed of two highly homologous isoforms, Stat5a and Stat5b, which display >90% amino acid identity and function as both signaling proteins and nuclear transcription factors. Activation of Stat5a/b occurs by phosphorylation of a conserved C-terminal residue by an upstream kinase, most commonly Jak2 in prostate cancer, which induces Stat5a/b dimerization, nuclear translocation and target gene regulation (27, 28) . Stat5a/b promotes growth of prostate cancer and tumor progression, critically sustaining viability of prostate cancer cells in vitro (18, 21) and xenograft tumor growth in vivo (19) . Stat5a/b is active in 95% of clinical CRPCs (29) , with the Stat5a/b gene locus amplified in 29% of distant CRPC metastases (30) . Additionally, high active Stat5a/b expression predicts early disease recurrence (24, 26) and prostate cancer-specific death (26) , and promotes metastatic behavior of prostate cancer cells in vitro and in vivo (22) , suggesting Stat5a/b involvement in clinical progression of prostate cancer. In further support of this concept, pharmacological targeting of Stat5a/b signaling blocked growth of not only primary (19, 31) but also CRPC xenograft tumors in nude mice (31) .
Stat5a/b regulation of prostate cancer cell viability involves both AR-dependent and ARindependent mechanisms (18, 19, 21, 25, 29) . We have shown previously that Stat5a/b and AR functionally synergize in prostate cancer to enhance nuclear localization and transcriptional activity of both proteins (29) . At the same time, it is well established that AR activity in prostate cancer is regulated not only at transcriptional level but also by translational and post-translational mechanisms (32) .
Recently, Stat5a/b was proposed to be involved in up-regulation of AR levels in prostate cancer cells when AR is liganded by androgens (25) Protein solubilization and immunoblotting. Cell pellets were solubilized in lysis buffer [10 mM Tris-HCl (pH 7.6), 5 mM EDTA, 50 mM sodium chloride, 30 mM sodium pyrophosphate, 50 mM sodium fluoride, 1 mM sodium orthovanadate, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 µg/ml pepstatin A and 2 µg/ml leupeptin] (19, 21, 22, 29) . Protein concentrations of were determined by simplified Bradford method (Bio-Rad). The primary antibodies used were: anti-Stat5a/b mAb (1:1000; BD Biosciences), anti-androgen receptor (AR) mAb (1:1000, BioGenex Laboratories, Fremont, CA), anti-prostate-specific antigen (PSA) pAb (1:1000; Dako, Glostrup, Denmark), anti-β-actin pAb (1:2000; Sigma-Aldrich).
Protein coimmunoprecipitation. LNCaP cells were infected with adenovirus expression PrlR
(MOI:4), serum-starved overnight in 0.5% FBS, and stimulated with or without 10 nM Prl and 1 nM DHT, 10 μM Bicalutamide, 10 μM Flutamide, or 10 μM MDV3100 for 1 h. Stat5a and Stat5b were immunoprecipitated from whole cell lysates with anti-Stat5a or anti-Stat5b (4 μl/ml; Millipore) vs. IgG from normal rabbit serum (4 μl/ml; Sigma). Antibodies were captured by incubation for 60 min with Chromatin immunoprecipitation (ChIP) assay. LNCaP cells were crosslinked with 1% formaldehyde, quenched with 125 mM glycine and solubilized in lysis buffer (10mM HEPES 7.5, 10mM
KCl, 1.5mM MgCl 2, 0.5mM DTT, 0.5% NP-40, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 µg/ml pepstatin A and 2 µg/ml leupeptin). Nuclei were pelleted from whole cell lysates and solubilized in nuclear lysis buffer (50mM Tris pH 8.0, 10mM EDTA, 1% SDS, 1 mM phenylmethylsulfonyl fluoride, 5 µg/ml aprotinin, 1 µg/ml pepstatin A and 2 µg/ml leupeptin). Nuclear lysates were sonicated to shear DNA, yielding fragments of approximately 500 bp. Extracts were pre-cleared using protein A sepharose Generation of Stat5a and AR deletion constructs. Full-length Stat5a and AR were amplified by polymerase chain reaction (PCR) and subcloned to pCMV-3FLAG vector (Stratagene, La Jolla, CA) with EcoRI and SalI sites. Stat5a deletion constructs were constructed by PCR-directed mutagenesis, with pCMV-3FLAG-Stat5a (full-length Stat5a) used as a template. PCR primers for each Stat5a deletion construct contain different Stat5a truncated boundary sequences. PCR products were digested with EcoRI/SalI and ligated with pCMV-3FLAG vector to form Stat5a deletion constructs and subjected to sequencing analysis for verification. Full-length AR was amplified by PCR and subcloned to pCMV-3MYC vector (Stratagene) with BamHI and XhoI sites. AR deletion constructs were then generated and verified as described for Stat5a deletion constructs.
Coimmunoprecipitation of FLAG-Stat5a and MYC-AR deletion constructs. PC-3 cells were co-transfected with plasmid pCMV-3FLAG-Stat5a deletion constructs, pCMV-3MYC-AR (full-length AR) and pPrlR (Fig. 3D ) or pCMV-3MYC-AR deletion constructs, pCMV-3FLAG-Stat5a (full-length Stat5a) and pPrlR ( 
Statistical analyses.
In experiments with two groups, groups were compared using two-sample ttests with unequal variances. In experiments with more than two groups, groups were compared using ANOVA allowing for unequal variances across groups. When the overall ANOVA test of group differences was significant, pairwise comparisons were performed. For nM dihydrotestosterone (DHT), however, induced nuclear localization of AR with concurrent increased nuclear localization of wild-type Stat5, phosphorylation-dead Stat5a(Y694F) and dominant-negative Stat5a/b (Fig. 1A) . These data indicate that transcriptionally active, phosphorylation-competent Stat5a/b is required for nuclear localization of unliganded AR in prostate cancer cells.
In a parallel set of experiments, serum-starved PC-3 cells were infected with adenovirus expressing wild-type Stat5a and prolactin receptor but not AR (Fig. 1B,i) or wild-type Stat5a and AR but not prolactin receptor (Fig. 1B,ii) . While direct Stat5a/b activation via prolactin stimulation still resulted in nuclear localization of Stat5a/b, in the absence of AR protein, the nuclear localization of Stat5a/b following DHT stimulation was not detectable (Fig. 1B,i) . Additionally, the absence of prolactin receptor to transduce signaling to Stat5a/b after prolactin stimulation abrogated not only nuclear localization of Stat5a/b, but of AR as well. However, DHT stimulation in the absence of prolactin receptor was still capable of increasing nuclear protein levels of not only AR, but also Stat5a/b (Fig. 1B,ii) . immunostaining of tumor sections accompanied by quantification ( Fig. 2A) . At the same time, AR immunostaining and quantification revealed that IST5-002 decreased nuclear AR protein levels in a dosedependent manner as well ( Fig. 2A) . Next, we analyzed a cohort of 443 clinical prostate cancer samples (Supplementary Table 1 protein levels were significantly associated with high AR protein levels (p<0.0001) (Fig. 2B) . In (Fig. 3A,i and ii) . In the next set of experiments, Stat5a/b signaling was blocked by treatment of the cells with Stat5a/b dimerization inhibitor IST5-002 (25 µM). Pharmacological inhibition of Stat5a/b decreased both PSA (p=0.029) and TMPRSS2 (p=0.078) mRNA expression to the same extent as genetic knockdown of Stat5a/b (Fig. 3A,i and ii) . This decrease in the expression of several AR target genes was not due to decreased AR mRNA expression, as AR mRNA levels remained unperturbed, or even slightly increased, 48 hours after Stat5a/b knockdown or IST5-002 treatment (Fig. 3A,iii) (Fig. 3D) . Analysis of the overlap of the domains represented by Stat5a-NTCCD, -N-ter and -C-ter suggest that the AR interaction site is localized to the N-terminal portion of the Stat5a DNA-binding domain.
In the reverse scenario, full-length FLAG-Stat5a was cotransfected into PC-3 cells along with each of the listed MYC-AR deletion constructs individually ( Fig. 3E; (Fig. 4A,i and ii). Treatment with 1 nM DHT reversed this trend and partially prevented down-regulation of AR protein levels (Fig. 4A,i) . Interestingly, Stat5a/b knockdown was almost as efficient as direct knockdown of AR (shAR) in decreasing AR protein levels (Fig. 4A,iii) . PSA protein levels were also diminished following Stat5a/b knockdown by Stat5a/b antisense oligonucleotides during this timeframe, presumably due to loss of AR protein (Fig. 4A,iii and iv) .
To assess if loss of AR protein after Stat5a/b knockdown was due to increased flux of AR through the proteasome, we initiated Stat5a/b knockdown followed by treatment with 10 µM proteasome inhibitor MG132. Proteasomal blockade partially rescued Stat5a/b knockdown-induced loss of AR, restoring AR protein levels in prostate cancer cells (Fig. 4B,i) . AR loss, and subsequent AR rescue through proteasome inhibition, was time-dependent, requiring prior Stat5a/b knockdown, which generally occurred hours after transduction of cells with lentiviral shStat5a/b (Fig. 4B,ii) . AR rescue could not be attributed to generation of new AR protein, since rescue of AR protein levels occurred to a comparable extent in the presence of both MG132 and protein synthesis inhibitor cyclohexamide (Fig. 4B,iii) . (Fig.   5D ). In all instances, antiandrogen-liganded AR or AR in the absence of Stat5a/b was subjected to enhanced degradation. Indeed, the combination of Stat5a/b knockdown and antiandrogen treatment reduced AR protein levels to a greater extent than either intervention alone in LNCaP cells (Fig. 5D,i) .
Enhanced proteasomal degradation of AR through combined Stat5a/b knockdown and antiandrogen treatment was partially rescued by treatment with MG132, as previously seen for each intervention individually (Fig. 5D,ii) . In conclusion, the data presented here indicate that Stat5a/b disruption potentiates AR proteasomal degradation induced by antiandrogens.
Combined inhibition of Stat5a/b and AR suppresses growth of prostate cancer cells to a greater extent than AR inhibition alone
To determine if pharmacological Stat5a/b inhibition potentiates the growth-inhibitory effects of antiandrogens, we evaluated the efficacy of combination therapy of antiandrogen MDV3100 and Stat5a/b dimerization inhibitor IST5-002 to MDV3100 alone in LNCaP cells. First, we determined sensitivity of LNCaP growth to MDV3100 (IC 50 = 90 µM) (Fig. 6A) or IST5-002 (IC 50 = 25 µM) (Fig. 6B) as single agents. Next, LNCaP cells were treated with increasing doses of MDV3100 either alone or in combination with 25 µM IST5-002 (IC 50 value). At every dose of MDV3100 tested, a combination of MDV3100 and IST5-002 inhibited growth of LNCaP cells to a greater extent than MDV3100 alone (p<0.0001) (Fig. 6C) .
Remarkably, the addition of IST5-002 decreased the IC 50 value of MDV3100 from 90 µM to approximately 5 µM in LNCaP cells, indicating substantial potentiation of antiandrogen action by Stat5a/b inhibition (p<0.0001) (Fig. 6Aiii) . Collectively, these results suggest that efficacy of interferes with some other event prior to AR being directed to the proteasome. AR ubiquitination depends on AR phosphorylation, with phosphorylated serine or tyrosine residues serving as recognition motifs for E3 ligases (phosphodegrons) (43, 46, 47) . Phospho-S515 and -Y534 of AR represent the degrons for E3 ligases Mdm2 (43, 46) and CHIP (46, 47) , respectively. Since our results show that Stat5a/b binds to the N-terminal region (aa 1-566) of AR, it is plausible that Stat5a/b hinders E3 ligase recruitment by masking the AR phosphodegrons. Analogous regulation of transcriptional activity and nuclear localization has been described for BRCA1 and BRCA2 via molecular masking of nuclear export signals by BARD in breast cancer (48, 49) . It is also possible that Stat5a/b-induced nuclear sequestration of AR in prostate 
